Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2025)
Historic Income from Continuing Operations for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.
- Beam Therapeutics' Income from Continuing Operations fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.9 million, marking a year-over-year decrease of 20228.73%. This contributed to the annual value of -$376.8 million for FY2024, which is 18424.88% down from last year.
- As of Q3 2025, Beam Therapeutics' Income from Continuing Operations stood at -$112.7 million, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Income from Continuing Operations registered a high of $142.8 million during Q4 2023, and its lowest value of -$200.4 million during Q1 2021.
- Over the past 5 years, Beam Therapeutics' median Income from Continuing Operations value was -$89.0 million (recorded in 2023), while the average stood at -$76.3 million.
- Per our database at Business Quant, Beam Therapeutics' Income from Continuing Operations crashed by 62193.24% in 2021 and then skyrocketed by 47227.31% in 2023.
- Beam Therapeutics' Income from Continuing Operations (Quarter) stood at -$64.7 million in 2021, then skyrocketed by 40.73% to -$38.3 million in 2022, then soared by 472.27% to $142.8 million in 2023, then tumbled by 163.33% to -$90.4 million in 2024, then fell by 24.68% to -$112.7 million in 2025.
- Its Income from Continuing Operations was -$112.7 million in Q3 2025, compared to -$102.3 million in Q2 2025 and -$109.4 million in Q1 2025.